for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Imv Inc

IMV.TO

Latest Trade

4.23CAD

Change

-0.09(-2.08%)

Volume

15,935

Today's Range

4.02

 - 

4.39

52 Week Range

3.06

 - 

8.49

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.32
Open
4.39
Volume
15,935
3M AVG Volume
0.64
Today's High
4.39
Today's Low
4.02
52 Week High
8.49
52 Week Low
3.06
Shares Out (MIL)
50.61
Market Cap (MIL)
214.09
Forward P/E
-8.68
Dividend (Yield %)
--

Next Event

Q3 2019 IMV Inc Earnings Call

Latest Developments

More

IMV Says QTRLY Loss Per Share $0.10

Imv Inc Reports Results From Mid-Stage Trial Testing Its Experimental Lymphoma Treatment

Imv Inc Q1 Loss Per Share C$0.13

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Imv Inc

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.

Industry

Biotechnology & Drugs

Contact Info

130 Eileen Stubbs Ave Suite 19

+1.902.4921819

https://imv-inc.com/

Executive Leadership

Andrew J. Sheldon

Chairman of the Board

Frederic Ors

Chief Executive Officer, Director

Pierre Labbe

Chief Financial Officer

Joseph Sullivan

Senior Vice President - Business Development

Marc Jasmin

Senior Director, Director of Investor Relations

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (CAD)

2016

-0.288

2017

-0.320

2018

-0.500

2019(E)

-0.488
Price To Earnings (TTM)
--
Price To Sales (TTM)
406.24
Price To Book (MRQ)
10.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
44.63
LT Debt To Equity (MRQ)
43.77
Return on Investment (TTM)
-85.70
Return on Equity (TTM)
-72.65

Latest News

BRIEF-Immunovaccine Announces $12.5 Million Bought Deal Offering

* IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer

* IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER

BRIEF-IMMUNOVACCINE AND LEIDOS EXPAND COLLABORATION TO DEVELOP MALARIA VACCINE CANDIDATES

* IMMUNOVACCINE AND LEIDOS EXPAND COLLABORATION TO DEVELOP MALARIA VACCINES FORMULATED IN DEPOVAX Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine reports qtrly loss per share of ‍$0.02​

* Immunovaccine announces third quarter 2017 financial results

BRIEF-Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac

* Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine receives an extension to the maturity date of its $5m loan until 2020

* Immunovaccine receives an extension to the maturity date of its $5m loan until 2020

BRIEF-Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines

* Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine Q2 loss per share C$0.02

* Immunovaccine announces financial results for quarter ended June 30, 2017

BRIEF-Immunovaccine announces achievement in personalized cancer medicines

* Immunovaccine achieves breakthrough in support of developing personalized cancer immunotherapies

BRIEF-Immunovaccine announces $10 million bought deal offering

* Immunovaccine Inc says intends to use net proceeds of offering to advance company's various depovax™-based products clinical studies

BRIEF-Immunovaccine says to initiate mid-stage trial of its blood cancer drug

* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug

BRIEF-Immunovaccine net loss, comprehensive loss of $2.4 mln for quarter ended March 31

* Immunovaccine announces financial results for quarter ended March 31, 2017

BRIEF-Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate

* Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate

BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study

* Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study evaluating immunovaccine's DPX-survivac with Merck's pembrolizumab

BRIEF-Immunovaccine presents preclinical research on novel monoclonal antibodies

* Immunovaccine Inc presents preclinical research at aacr 2017 on ability of novel monoclonal antibodies to boost efficacy of depovax(tm)-based cancer immunotherapy

BRIEF-Immunovaccine announces positive interim clinical data from Ovarian cancer study

* Immunovaccine announces positive interim clinical data from ovarian cancer study of DPX-survivac in combination with epacadostat

BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies

* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug

BRIEF-Immunovaccine appoints Pierre Labbe as CFO

* Immunovaccine appoints seasoned financial executive Pierre Labbe as CFO

BRIEF-Immunovaccine's DPX-Survivac gets orphan drug designation by European medicines agency

* The european medicines agency grants orphan drug designation status to Immunovaccine's DPX-Survivac in ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine provides update on preclinical study

* Neoepitope peptides formulated in immunovaccine's depovax(tm) vaccine platform show significant positive results in preclinical studies Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up